Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification
- PMID: 6644423
- DOI: 10.1016/s0022-3476(83)80706-9
Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification
Abstract
The medical records of 47 children with dermatomyositis who were seen in the pediatric rheumatology clinic at the University of Michigan between 1964 and 1982 were reviewed. Although most children with dermatomyositis have a good prognosis, the best predictor of both good functional recovery and minimal calcinosis is early treatment after the onset of symptoms, using high doses of prednisone for an adequate length of time. Of the children given such treatment, 78% had good functional outcomes, and disabling calcinosis was seen in 20% or less. Children given treatment late in the course of disease and with low doses of steroids are more likely to be functionally limited and have a greater amount of dystrophic calcium salt deposition. In our study, only 33% of patients given such treatment had a mild disease course with good functional outcome. We have identified a subgroup of children with dermatomyositis who appear to do poorly despite optimal therapeutic regimens. These patients are distinguished by a severe disease course responding minimally to corticosteroid therapy and manifested by persistent muscle weakness, elevations of muscle enzyme activity, and severe generalized cutaneous vasculitis. These children are at high risk for the development of exoskeleton-like calcification; consideration should be given to combined immunosuppressive therapy early in the course of disease.
Similar articles
-
Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis.J Am Acad Dermatol. 2002 Oct;47(4):505-11. doi: 10.1067/mjd.2002.122196. J Am Acad Dermatol. 2002. PMID: 12271292
-
Vasculitis and calcinosis in juvenile dermatomyositis.Acta Univ Carol Med (Praha). 1991;37(1-2):8-15. Acta Univ Carol Med (Praha). 1991. PMID: 1845413
-
[Calcinosis of childhood dermatomyositis. Apropos of 10 cases].Helv Paediatr Acta. 1984 Mar;39(1):47-54. Helv Paediatr Acta. 1984. PMID: 6724996 French.
-
The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis.Curr Rheumatol Rep. 2014 Dec;16(12):467. doi: 10.1007/s11926-014-0467-y. Curr Rheumatol Rep. 2014. PMID: 25366934 Free PMC article. Review.
-
Update on the treatment of calcinosis in dermatomyositis.Rev Bras Reumatol. 2013 Apr;53(2):211-4. Rev Bras Reumatol. 2013. PMID: 23856799 Review. English, Portuguese.
Cited by
-
Juvenile Dermatomyositis.J Rheum Dis. 2022 Jan 1;29(1):14-21. doi: 10.4078/jrd.2022.29.1.14. J Rheum Dis. 2022. PMID: 37476697 Free PMC article. Review.
-
A Path to Prediction of Outcomes in Juvenile Idiopathic Inflammatory Myopathy.Front Immunol. 2019 Apr 2;10:638. doi: 10.3389/fimmu.2019.00638. eCollection 2019. Front Immunol. 2019. PMID: 31001260 Free PMC article. Review.
-
Marked improvement of calcinosis in adult dermatomyositis with etidronate therapy.J Bone Miner Metab. 2012 Jan;30(1):114-8. doi: 10.1007/s00774-011-0289-1. Epub 2011 Jun 28. J Bone Miner Metab. 2012. PMID: 21710176
-
Lower extremity lipedema, upper extremity lipodystrophy and severe calcinosis complicating juvenile dermatomyositis.Rheumatol Int. 2014 Nov;34(11):1615-8. doi: 10.1007/s00296-014-3031-1. Epub 2014 May 1. Rheumatol Int. 2014. PMID: 24789670
-
Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome.Rheumatol Int. 2016 Jul;36(7):961-5. doi: 10.1007/s00296-016-3467-6. Epub 2016 Mar 23. Rheumatol Int. 2016. PMID: 27007612
MeSH terms
Substances
LinkOut - more resources
Full Text Sources